Alterity Therapeutics (NASDAQ:ATHE) Rating Lowered to Hold at Benchmark

Alterity Therapeutics (NASDAQ:ATHE) was downgraded by Benchmark from a “speculative buy” rating to a “hold” rating in a research note issued on Monday, MarketBeat reports.

Separately, Maxim Group boosted their target price on Alterity Therapeutics from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, January 30th.

Alterity Therapeutics Trading Down 9.6 %

Shares of ATHE opened at $4.51 on Monday. The firm has a 50-day simple moving average of $2.93 and a two-hundred day simple moving average of $1.87. Alterity Therapeutics has a 1-year low of $1.00 and a 1-year high of $5.87.

Hedge Funds Weigh In On Alterity Therapeutics

An institutional investor recently raised its position in Alterity Therapeutics stock. HB Wealth Management LLC lifted its stake in shares of Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 31,883 shares of the company’s stock after buying an additional 8,100 shares during the quarter. HB Wealth Management LLC owned approximately 0.44% of Alterity Therapeutics worth $110,000 at the end of the most recent reporting period. Institutional investors own 2.14% of the company’s stock.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.